 |
A study of intravenous rituximab (Rituxan®, Genentech and Biogen Idec) in 439 people with primary progressive MS has shown that the drug did not slow disease progression when compared with inactive placebo, the primary endpoint of the study.
To read more, as reported by the US National MS Society, click here.
Source: US National MS Society
|
